This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- Summary: Appropriate Use Criteria for Estrogen Receptor-Targeted PET Imaging with 16{alpha}-18F-Fluoro-17{beta}-Fluoroestradiol
- 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials
- 18F-Fluoroestradiol PET: Current Status and Potential Future Clinical Applications
- Pharmacodynamic Imaging Guides Dosing of a Selective Estrogen Receptor Degrader
- Feasibility and Predictability of Perioperative PET and Estrogen Receptor Ligand in Patients with Invasive Breast Cancer
- Small-Animal PET of Steroid Hormone Receptors Predicts Tumor Response to Endocrine Therapy Using a Preclinical Model of Breast Cancer
- Oestrogen-related tumour phenotype: positron emission tomography characterisation with 18F-FDG and 18F-FES
- PET Imaging of Estrogen Receptors as a Diagnostic Tool for Breast Cancer Patients Presenting with a Clinical Dilemma
- Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast Cancer
- Radiopharmaceuticals in Preclinical and Clinical Development for Monitoring of Therapy with PET
- Assessment of Human Biodistribution and Dosimetry of 4-Fluoro-11{beta}-Methoxy-16{alpha}-18F-Fluoroestradiol Using Serial Whole-Body PET/CT
- 7{alpha}-18F-Fluoromethyl-Dihydrotestosterone and 7{alpha}-18F-Fluoromethyl-Nortestosterone: Ligands to Determine the Role of Sex Hormone-Binding Globulin for Steroidal Radiopharmaceuticals
- Preclinical Development of a Neutral, Estrogen Receptor-Targeted, Tridentate 99mTc(I)-Estradiol-Pyridin-2-yl Hydrazine Derivative for Imaging of Breast and Endometrial Cancers
- Tumor Receptor Imaging
- Application of PET/CT in the Development of Novel Anticancer Drugs
- Nuclear Imaging Probes: from Bench to Bedside
- Positron Emission Tomography As an Imaging Biomarker
- The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development
- FDG-PET and Beyond: Molecular Breast Cancer Imaging
- Receptor Imaging in Oncology by Means of Nuclear Medicine: Current Status
- In Vivo Prediction of Response to Antiestrogen Treatment in Estrogen Receptor-Positive Breast Cancer
- [18F]Fluoroestradiol Radiation Dosimetry in Human PET Studies